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Background: Incidence and prognostic implication of myocardial injury after transcatheter aortic valve replacement (TAVR) have not been studied 
consistently. Our aim was to assess incidence and extent of myocardial injury in transfemoral (TF) vs. transapical (TA) approaches.
Methods: Clinical data of aortic stenosis patients undergoing TAVR was retrospectively analyzed. Myocardial necrosis markers (troponin I (TnI) and 
CPK-MB) were assessed during hospitalization. Echocardiographic data for a subset of patients undergoing TA-TAVR was retrospectively reviewed for 
assessment of regional post procedural apical dysfunction.
Results: A total of 150 patients underwent TAVR, 103 (69%) had TF and 47 (31%) had TA approach. Baseline characteristics were comparable 
between groups, excluding PVD. Peak TnI levels were above normal value in nearly all patients. TA patients had significantly higher myocardial enzyme 
leakage as compared to TF patients (p <0.001). (Table) In multivariable analysis neither TnI (OR 1.02; 95% CI of 0.98-1.06) nor CPK-MB (OR 1.01; 
95% CI of 0.98-1.03) were associated with 30-day mortality. Among 28 of TA patients who had apical motion assessment on echocardiography, 21% 
had apical motion abnormalities that improved at long-term follow-up.
Conclusions: Patients undergoing TA TAVR have significantly higher myocardial enzyme leak. This leakage is not translated into procedural outcome 
differences. Transient apical motion abnormality is seen in a small subset of TA patients.
 
